Shares of Intermune (ITMN +16.3%) are higher today after handily beating Q3 estimates late...

|By:, SA News Editor

Shares of Intermune (ITMN +16.3%) are higher today after handily beating Q3 estimates late yesterday. Net losses narrowed to $45.4M, or $0.70 per share, compared with a net loss of $38.2M, or $0.63 per share in the prior-year period. Sales of its lung-disease drug Esbriet have been strong, and the company says it expects FY12 sales to come in at or slightly above the high end of its estimated range. Canaccord ups the shares to Buy on the momentum.